

11-22-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Anthony et al.

Serial No.:

09/973,853

Case No.: 20757Y

Art Unit:

1624

Filed:

October 10, 2001

Examiner:

For:

AZA- AND POLYAZA-NAPHTHALENYL

CARBOXAMIDES USEFUL AS INTEGRASE

INHIBITORS

Coleman, Brenda L.

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT OF THE SUBSTANCE OF THE INTERVIEW

Sir:

A Notice of Allowance and a Notice of Allowability were mailed on November 12, 2004. The Notice of Allowability included an Interview Summary of a telephonic interview conducted on November 10, 2004 between the Examiner and the undersigned. The Interview Summary required Applicants to file a statement of the substance of the interview no later than one month from the mailing date of the Interview Summary (i.e., by December 12, 2004). A statement of the substance of the interview is as follows:

The interview was a telephonic interview held on November 10, 2004 between Examiner Coleman and the undersigned. No exhibit was shown and no demonstration was conducted. The claim discussed during the interview was claim 21. No prior art was discussed. The Examiner requested that claim 21 be rewritten as an independent claim, because the claim contained at least one species that was outside the scope of claim 1 as amended in the amendment filed October 22, 2004. The undersigned agreed to the Examiner's request and authorized the Examiner to amend claim 21. The undersigned also authorized the Examiner to charge any fees that may be due as a result of the amendment to Merck's Deposit Account.

As a result of the interview and the agreed upon amendment to claim 21, the Examiner indicated that she would allow the application.

Respectfully submitted,

By:

Kenneth R. Walton, Reg. No. 32,951

Attorney for Applicants MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

Tel.: (732) 594-3462

Date: November 19, 2004